Fusobacteriota: What a Stool Microbiome Result Means

A bacterial phylum often found at low abundance

Fusobacteriota is a bacterial group that includes the genus Fusobacterium. An entry in a microbiome report usually describes the relative share of its DNA in a stool sample. Testing may use 16S rRNA gene analysis or shotgun metagenomics. How precisely species are distinguished, and how sensitively small quantities are detected, depends on the method. A result that is not reported as detected therefore does not prove the bacteria are absent.

Fusobacterium nucleatum is a particular focus of research. It occurs in the mouth and has also been found in colorectal tumors. A 2024 primary study showed that one particular subgroup was especially enriched in colorectal cancer tissue. That is an important biological finding, but it does not establish that the total Fusobacteriota percentage in stool can determine your personal cancer risk.

What measuring this phylum can show

The analysis first shows which DNA was detected in the sample. It cannot establish whether bloating, loose stools and bleeding gums have the same cause. Nor can one percentage demonstrate that bacteria traveled from the mouth to the gut.

Research on the oral-gut connection investigates matching bacterial strains in the mouth and tumor tissue, as well as possible routes of spread. Some mechanistic findings come from cell and animal experiments. In practice, the specific symptoms matter: gum problems call for dental assessment, and persistent bowel symptoms need medical evaluation. A microbiome profile cannot replace either.

Interpreting low, moderate and higher results

There is no generally accepted healthy target range for the Fusobacteriota proportion. Labels such as “low,” “moderate” and “high” usually refer to the provider’s comparison data. A low result proves neither a high-fiber diet nor an intact gut barrier; a high result does not automatically indicate inflammation or a tumor.

Relative numbers also need context. A higher percentage can arise because other bacteria have decreased. Different species and subgroups cannot simply be assessed as one. Cancer research on particular F. nucleatum subgroups should therefore not be generalized to all Fusobacteriota.

Individual cases of invasive F. nucleatum infection have been reported in pregnancy. One case report found the organism in the placenta and fetus, with a matching strain in the mother’s mouth. An ordinary stool finding is a different situation and cannot support that kind of risk prediction.

What the finding means and where its limits lie

Stool does not contain the same bacterial community as a tissue sample. A tumor-research finding therefore cannot be directly compared with a home test, even before considering differences in storage, sequencing and analysis.

Sufficient clinical evidence for routine microbiome testing and treatments derived from it is lacking, as the international consensus on microbiome testing explains. Adding inflammation or metabolic tests does not automatically make a Fusobacteriota percentage diagnostically useful. Each additional investigation needs its own medical question.

Colorectal cancer screening uses established methods, including tests for hidden blood in stool and colonoscopy. The National Cancer Institute overview explains these approaches. An unremarkable Fusobacteriota result is no reason to skip recommended screening.

Frequently asked questions

What does a Fusobacteriota test measure?

The microbiome profile described here assigns bacterial DNA from stool to groups and usually reports relative abundance. A 16S analysis examines bacteria, not fungi. Shotgun metagenomics can investigate more organisms and genes, but that still does not measure their actual metabolic activity.

How is the sample collected?

Usually, you collect a small stool sample at home using the kit materials. Follow the laboratory’s specific instructions for the container, labeling, storage and shipping. Avoid contamination and wash your hands before and after collection.

What can the results tell me about my health?

The result describes the composition of the sample tested. It measures neither nutrient absorption nor gut-barrier function, mood or general inflammation. Associations between particular Fusobacterium strains and disease are research findings, not a personal health assessment derived from one percentage.

How accurate and reliable are Fusobacteriota tests?

That cannot be quantified without details of the specific test. Sequencing methods differ in detection limits and resolution; not every method distinguishes closely related species or strains. A reliable technical measurement is also different from a test that reliably identifies a disease.

How often should I test Fusobacteriota?

There is no established interval for routine monitoring. Neither a dietary change nor probiotic use, by itself, justifies repeated measurements. The deciding question is whether the result would change a specific, medically justified decision.

Can Fusobacteriota populations change quickly?

Microbial composition can change. For Fusobacteriota, however, there is no universal timetable for a result to respond to new habits or stabilize. Differences between samples can have biological and technical causes. Do not change or stop medicines specifically for a microbiome test unless that has been agreed with your clinician.

Are the results diagnostic?

The abundance reported in this microbiome profile diagnoses neither cancer nor infection. A low result does not exclude those conditions either. Targeted testing for a suspected pathogen is a different investigation, chosen according to the clinical situation.

How should I respond to my Fusobacteriota result?

An unusual proportion alone is not a reason to take antibiotics or probiotics, or adopt a restrictive diet. If needed, discuss the report alongside your actual symptoms. Symptom history, oral health, medicines and previous medical assessment are more useful for deciding what to do next than trying to reduce one bacterial percentage.

Sources and literature

• Jovel J, Patterson J, Wang W, Hotte N, O’Keefe S, Mitchel T, Perry T, Kao D, Mason AL, Madsen KL, Wong GK (2016). Characterization of the gut microbiome using 16S or shotgun metagenomics. Frontiers in Microbiology, 7, 459. https://doi.org/10.3389/fmicb.2016.00459 Source

• Ou S, Wang H, Tao Y, Luo K, Ye J, Ran S, Guan Z, Wang Y, Hu H, Huang R (2022). Fusobacterium nucleatum and colorectal cancer: From phenomenon to mechanism. Frontiers in Cellular and Infection Microbiology, 12, 1020583. https://doi.org/10.3389/fcimb.2022.1020583 Source

• Allaband C, McDonald D, Vázquez-Baeza Y, Minich JJ, Tripathi A, Brenner DA, Loomba R, Smarr L, Sandborn WJ, Schnabl B, Dorrestein P, Zarrinpar A, Knight R (2019). Microbiome 101: Studying, analyzing, and interpreting gut microbiome data for clinicians. Clinical Gastroenterology and Hepatology, 17(2), 218-230. https://doi.org/10.1016/j.cgh.2018.09.017 Source

• Zepeda-Rivera M et al. (2024). A distinct Fusobacterium nucleatum clade dominates the colorectal cancer niche. Nature, 628, 424–432. Study

• Han YW et al. (2010). Term stillbirth caused by oral Fusobacterium nucleatum. Obstetrics & Gynecology, 115, 442–445. Case report

• Porcari S et al. (2025). International consensus statement on microbiome testing in clinical practice. Lancet Gastroenterology & Hepatology, 10, 154–167. Full text

• National Cancer Institute. Screening Tests to Detect Colorectal Cancer and Polyps. Information

Origin and source context

Adapted for Nutrient Desk from the original article, with context from the sources listed. Research findings involving particular subgroups and tissue samples should be distinguished from interpretation of a general stool profile.